Chordia Therapeutics Income Statement

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Aug '26 Aug 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Revenue	-	-	-	2,500
Revenue Growth	-	-	-	-
Gross Profit	-	-	-	2,500
Selling, General & Admin	318.99	364.47	301.6	291.12
Research & Development	1,155	1,425	1,500	1,997
Operating Expenses	1,474	1,790	1,801	2,288
Operating Income	-1,474	-1,790	-1,801	212.06
Currency Exchange Gain (Loss)	-10.37	-3.9	-3.6	-12.24
Other Non Operating Income (Expenses)	34.01	10.23	-19.71	25.95
EBT Excluding Unusual Items	-1,450	-1,783	-1,825	225.76
Asset Writedown	-2.6	-	-	-
Pretax Income	-1,453	-1,783	-1,825	225.76
Income Tax Expense	2.42	2.42	2.42	2.42
Net Income	-1,455	-1,786	-1,827	223.34
Net Income to Common	-1,455	-1,786	-1,827	223.34
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	74	69	59	56
Shares Outstanding (Diluted)	74	69	59	56
Shares Change	7.45%	16.82%	4.05%	-
EPS (Basic)	-19.74	-26.03	-31.11	3.96
EPS (Diluted)	-19.74	-26.03	-31.11	3.96
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Aug '26 Aug 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Free Cash Flow	-1,421	-1,842	-1,938	543.38
Free Cash Flow Per Share	-19.28	-26.85	-32.99	9.63
Gross Margin	-	-	-	100.00%
Operating Margin	-	-	-	8.48%
Profit Margin	-	-	-	8.93%
Free Cash Flow Margin	-	-	-	21.73%
EBITDA	-1,471	-1,787	-1,797	218.1
EBITDA Margin	-	-	-	8.72%
D&A For EBITDA	2.7	2.7	4.09	6.04
EBIT	-1,474	-1,790	-1,801	212.06
EBIT Margin	-	-	-	8.48%
Effective Tax Rate	-	-	-	1.07%